Curi Bio
Curi Bio provides integrated platforms that combine advanced 3D human tissue models, biosystems for functional analysis, and AI-enabled data analytics to support drug discovery and preclinical R&D. Its products and services are used by pharmaceutical and biotechnology companies to improve the predictive accuracy of drug safety, efficacy, and potency assessments, with a focus on cardiac, skeletal muscle, and disease models. The organization aims to accelerate the development of next-generation human medicines by integrating human cells, systems, and data.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2015
- Type
- Corporation Seattle business license
- Employees
- 51
- Registered name
- Nanosurface Biomedical Inc Seattle business license
- Stage
- Series B
- Founders
- Elliot Fisher
Is this your organization? Claim it
Seattle Biotech Startup Curi Bio Raises $10M Led by DreamCIS to Advance 3D Tissue Drug Discovery Platforms
Seattle biotech startup Curi Bio raised $10 million in Series B funding led by DreamCIS to expand its R&D platform using 3D tissue models for drug discovery. The company serves major pharmaceutical firms and aims to develop new platforms for various muscle and metabolic diseases.
Curi Bio raises $10M Series A to advance Mantarry stem cell drug-discovery platform
Seattle startup Curi Bio raised $10 million in Series A to advance its Mantarry stem cell-focused drug discovery platform and expand the business.
Curi Bio raises $10M to advance iPSC-based 3D tissue drug-discovery platforms including Mantarray
Seattle-based Curi Bio raised $10 million in Series A financing to advance its human iPSC-based drug discovery platforms, including 3D engineered tissue products like Mantarray and Cytostretcher. The company provides customized assay and screening services for cardiac, musculoskeletal and neuromuscular models and has prior funding including $6M this spring and over $6M in NIH grants.
By Curi Bio
Curi Bio closes $10M oversubscribed Series A led by Dynamk Capital with new investors UTC Investment and DS Asset Management
Curi Bio closed a $10M oversubscribed Series A second closing to scale its human stem cell–based Curi Engine and Mantarray platforms, aiming to accelerate development of 3D engineered muscle tissue models for drug discovery.
People
-
Elliot Fisher Co-Founder & Chief Business Officer
-
Michael Cho Executive, Chief Strategy Officer
-
Nicholas Geisse Executive, Chief Executive Officer
Online
Questions about Curi Bio
What is Curi Bio?
Curi Bio is a startup based in Seattle, Washington, US that provides integrated platforms combining 3D human tissue models, functional analysis biosystems, and AI-enabled data analytics for drug discovery and preclinical R&D.
What is Curi Bio known for?
Curi Bio is known for tools that help pharmaceutical and biotechnology companies assess drug safety, efficacy, and potency, with a focus on cardiac, skeletal muscle, and disease models.
What has Curi Bio been in the news for?
GeekWire reported in December 2025 on Curi Bio’s work to advance 3D tissue drug discovery platforms. In December 2021, GeekWire covered Curi Bio’s iPSC-based 3D tissue drug-discovery platforms, including Mantarray.
Who are the people behind Curi Bio?
Elliot Fisher is co-founder and chief business officer at Curi Bio. Nicholas Geisse is chief executive officer, and Michael Cho is chief strategy officer.
Who invested in Curi Bio, and how much has it raised?
Members of Seattle Flow see Curi Bio's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Curi Bio based?
Curi Bio is based in Seattle, Washington, US.